Western Regional Blog – BC, YK, AB, NWT and Nunavut
“As our initial goal was identification of bonafide clear cell carcinoma cell lines, we are pleased to report that the majority of reported CCC lines were representative of the primary tumors’ molecular and pathological phenotype.”
Objective To examine the relationship of ovulation-inducing drugs and ovarian cancer.
Design Retrospective cohort study, with additional follow-up since initial report.
Setting Five large reproductive endocrinology practices.
Patient(s) In a retrospective cohort of 9,825 women evaluated for infertility at five clinical sites in the United States between 1965 and 1988 with follow-up through 2010, we examined the relationship of ovulation-inducing drugs and ovarian cancer (n = 85).
Main Outcome Measure(s) Hazard rate ratios (RR) and 95% confidence intervals (CI) for ovarian cancer.
Result(s) Among women evaluated for infertility, there was no association of ovarian cancer risk with ever use of clomiphene citrate (CC) (adjusted RR 1.34, 95% CI 0.86–2.07) or gonadotropins (RR 1.00, 95% CI 0.48–2.08) and no evidence that any of several more detailed subgroups of usage were related to an increased risk with one exception: women who used CC and remained nulligravid did demonstrate much higher risks than those who successfully conceived compared with nonusers (respectively, RR 3.63, 95% CI 1.36–9.72 vs. RR 0.88, 95% CI 0.47–1.63).
Conclusion(s) Our overall results were reassuring and consistent with other studies. A reason for an association between CC use and ovarian cancer among persistently nulligravid women remains to be determined. Given the large and increasing number of women treated with ovulation-inducing drugs, the increased risk of ovarian cancer among the subset of women who remained nulligravid should be further monitored.
Britton Trabert, Emmet J. Lamb, Bert Scoccia, Kamran S. Moghissi, Carolyn L. Westhoff, Shelley Niwa, Louise A. Brinton